Simple: Doctors using Koios Medical's AI powered software catch more cancers earlier, before it’s too late; while simultaneously avoiding stressful, painful, costly overtreatment. Commercial payers have taken notice, incentivizing adoption and contributing to triple digit company growth.

Few moments are more devastating than a cancer diagnosis, except when learning it was missed the first time. Koios detects cancers early, when they are often invisible to humans, using the world’s leading FDA-cleared AI powered software as a medical device (SaMD) for ultrasound cancer diagnostics.

Physicians using Koios DS also avoid up to 60% of today’s “false positives”. Precision medicine powered by AI. Koios detects both suspicious and benign tissues extremely accurately. Peace of mind, anxiety gone, no discomfort or expense associated with biopsies that prove “negative, no trouble found.”

Koios DS software is already saving the healthcare system millions. Commercial insurance companies reimburse providers for the use of this innovative software, encouraging expanded and accelerated adoption.

The Koios value proposition packs another powerful component. Time. Diagnostic workflows are dramatically streamlined giving back precious time to overworked and scarce critical resources: Physicians and Sonographers. Ultrasound exams and interpretations are time consuming and complex, experiencing high degrees of variability in interpretation. With efficiency focused AI, Koios customers experience 30% efficient gains. One more patient per hour, eight more patients per day. Benefits add up quickly.

Koios DS software delivers a nearly instantaneous return on investment (ROI).

Our patented SmartUltrasound™ is trusted in 1,000+ hospitals and clinics across 30+ countries, diagnosing breast and thyroid cancer for many of the world’s top institutions — including Mayo Clinic, Mount Sinai, Northwestern, Memorial Sloan Kettering, Georgetown Medstar, Sutter Health, Mass General Brigham, and many more.

Named one of Newsweek’s Best-Rated AI Technologies in Healthcare, Koios is backed by Mitsui & Co. and partnering with global leaders GE Healthcare, Philips, and Change Healthcare.

With FDA clearance, insurance reimbursement, and profitability on the horizon, Koios stands at the forefront of a $2+ billion global market redefining ultrasound and medical imaging AI.

Our mission is clear & purposeful: Empower physicians with the best possible solutions to improve diagnostic accuracy, to provide healthcare at a lower cost, and to achieve better outcomes. Simply put, we enable physicians around the world to Be Koios Confident™.

Ultrasound is one of the most widely used imaging modalities in medicine; the safest, but also the least reliable.

*Stats for breast cancer.

Every year, 1 in 6 cancers are missed on ultrasound because ultrasound accuracy depends on the human eye, which has limits. Even the best-trained physicians interpret the same image differently, and some even disagree with themselves, later changing their diagnosis.

Data above comes from internal studies and research performed by Koios

(WHO, World Cancer Research Fund)

Meanwhile, the strain on our healthcare system is growing. The global shortage of radiologists is leaving hospitals overwhelmed, with doctors forced to read faster with fewer resources. Even after exams are completed, doctors often feel uncertain, leading patients to undergo painful, costly biopsies that prove unnecessary.

Across every demographic, economic and racial disparities widen the gaps in diagnosis and quality care. The result is a systemic problem in medical imaging that is inconsistent, inefficient, and dangerously dependent on human variability.

Medicine is only as good as its ability to see clearly. Right now, ultrasound exams being read without Koios are still being read in the dark.

At Koios Medical, we are transforming how physicians detect and diagnose cancer. Our patented, FDA-cleared SmartUltrasound™ is the world’s most widely adopted computer vision AI solution for ultrasound cancer diagnostics.

Ultrasound remains one of the most commonly used diagnostic tools in medicine — safe, accessible, and noninvasive — but its images can be complex and often difficult to interpret. Our SmartUltrasound™ applies advanced computer vision AI to every pixel, every frame, translating uncertainty into insight.

Today, SmartUltrasound™ is FDA-cleared and clinically proven for breast and thyroid cancer detection and diagnosis, two of the most frequently occurring cancers worldwide.

Koios DS analyzes millions of microscopic details invisible to the human eye and instantly determines whether tissue looks safe, benign, suspicious, or malignant, giving doctors an objective, data-driven assessment in seconds.

Our AI is trained on millions of biopsy-confirmed images — what medicine calls “ground truth” — representing the collective knowledge of thousands of physicians and pathologists combined into a software that is able to fully automate a clinical interpretation and report.

SmartUltrasound™ does not guess, it recognizes. It identifies patterns invisible to the human eye that have already been proven in clinical reality, connecting what’s seen on screen to what’s been verified in the lab.

SmartUltrasound™ integrates seamlessly into the systems physicians already use today. Available directly on GE Healthcare scanners, integrated with Philips images, and within all major image storage and hospital reporting systems.

With a single click, Koios AI runs silently in the background, interpreting images, aligning results with breast and thyroid imaging, reporting, and data systems (BI-RAD/TI-RAD), to prepare a structured report that elevates every exam with the confidence of consistency.

You wouldn’t write without spell check. You wouldn’t drive without GPS. And soon, we believe you won’t get an ultrasound without Koios.

Koios is rapidly becoming the new standard of care.

Koios AI makes already brilliant physicians superhuman. Increased accuracy saves time and avoids overtreatment, costing our strained healthcare system hundreds of millions in late-stage treatment and avoidable procedures. Physicians can do in seconds what used to take minutes. The savings add up.

SmartUltrasound™ turns ultrasound from one of medicine’s most variable imaging tools into one of its most consistent. In clinical studies, Koios reduces diagnostic variability by 41% and reading time by 24%, while helping physicians detect more cancers at earlier, more treatable stages.

With Koios, physicians read faster and act sooner. Hospitals gain efficiency with streamlined operations, lower costs, and fewer unnecessary procedures. And patients get answers that can stop cancer before it spreads.

With less than $38M+ raised to date from leading VCs and healthcare investment conglomerate Mitsui & Co., Koios is FDA-cleared, patented, and trusted in more than 1,000+ hospitals and clinics across 30+ countries. More than 50% of the 30 top cancer centers in the US depend on Koios DS software.

As adoption accelerates, Koios KPIs are signaling success. Annual recurring revenue has more than tripled over the past three years and hit $5M in 2025.

Growth is driven by resource shortages, growing awareness of AI, robust clinical evidence, and all combined with insurance reimbursement. Subscription renewals over 95% and expanding hospital installations with patient analyses performed up 300%+ year-over-year.

Forward-looking projections are not guaranteed.

Partnerships with two of the world’s largest medical imaging companies, GE Healthcare and Philips, have resulted in Koios’ technology being built directly into ultrasound scanners, third-party software, and distributed globally.

These integrations unlock access to tens of thousands of physicians working in hospitals and clinics. Koios can reach nearly any institution and clinician in the world through the partnerships created with these incumbent global leaders.

In the U.S., partnerships with Optum, a leading healthcare services organization, and SimonMed Imaging, one of the largest outpatient imaging networks, expand access across major health system providers and payers.

Koios’ portfolio of over a dozen issued and pending patents protects its core AI algorithms, intellectual property, data pipeline, and integration frameworks, fortifying its competitive moat in the wake of accelerating global adoption.

Koios’s SmartUltrasound™ technology is used by the most respected names in medicine, including Mayo Clinic, Mount Sinai, Mass General Brigham, Yale New Haven Health, Memorial Sloan Kettering, among other leading cancer centers.

It is deployed in more than half of the US News top 30 cancer hospitals in the U.S., making it one of the most widely adopted AI platforms in medical imaging.

Our AI software performance has been tested and validated in 19 peer-reviewed clinical studies, with top radiologists calling Koios their “second set of eyes” in the fight against missed cancers.

Koios is led by a seasoned team of healthcare innovators and engineers with decades of experience across radiology, medical AI, and imaging software. Our leaders have built and scaled technologies from concept to global adoption, used by GE Healthcare, Philips, Mount Sinai, Optum, Memorial Sloan Kettering, and even the U.S. Department of Defense.

Our co-founding engineers began their careers building advanced pattern recognition systems for national defense, technology that could detect faces, weapons, and hidden threats in complex environments.

That same expertise now powers SmartUltrasound™, helping physicians identify cancer earlier and more accurately than ever before. Management brings prior healthcare, IT, and imaging informatics, along with clinical experience specific to ultrasound diagnostics.

Ultrasound ranks as one of the most widely used and accessible imaging modalities in medicine, performing more than 400 million exams every year across hospitals, clinics, and private practices.

The market value of ultrasound is projected to reach $13 billion globally by 2028 as new applications, lower costs, and portable devices expand access worldwide.

At the same time, the medical imaging AI market is projected to exceed $14 billion globally, growing more than 20% annually as hospitals adopt AI solutions to improve accuracy, efficiency, and reimbursement.

SmartUltrasound™ sits squarely at the intersection of these two surging markets. In the U.S. alone, more than 8 million breast and thyroid ultrasound exams each year are eligible for Koios use, representing an estimated $400 million annual revenue opportunity.

Data above comes from internal studies and research performed by Koios

As insurance reimbursement expands and partnerships with GE Healthcare and Philips accelerate adoption, Koios is positioned to capture meaningful market share in a massive, underpenetrated global category.

Forward-looking projections are not guaranteed.

Koios operates a Software-as-a-Service (SaaS) model, generating recurring revenue by selling annual subscriptions to hospitals, health systems, and radiology groups. Pricing scales with usage, from individual physicians and small clinics to full enterprise integrations across hospital networks.

Each SmartUltrasound™ subscription includes reimbursement support, meaning hospitals are paid by insurers for use of Koios software for eligible exams. Reimbursement creates a powerful incentive for adoption and ensures every installation is a recurring revenue stream, generating a nearly immediate return on investment for each Koios customer.

Revenue growth is built on direct sales and distribution partnerships. GE Healthcare, Philips, and a network of distributor partners from Switzerland to Thailand, Israel to Istanbul, SmartUltrasound™ is becoming the global standard for ultrasound +AI.

Koios also offers customers a low-risk, low-cost risk and revenue-sharing pricing model, along with multi-year enterprise contracts to expand scalability across major health systems worldwide rapidly.

Over the past two years, Koios has grown its installed base by nearly 300%. Annual recurring revenue has more than tripled year-over-year since 2023, driven by insurance reimbursement and original equipment manufacturer (OEM) and other strategic partnerships.

Cost controls over the past two years have reduced monthly expenses by over 30%. We have adopted the use of AI internally to improve our own efficiency, which will help accelerate our path to profitability.

TCV (total contract value) exceeded $4.5M in 2025, and profitability is on the horizon as subscription renewals, enterprise contracts, and reimbursement-based usage compound growth, both domestically and overseas.

Forward-looking projections are not guaranteed.

Beyond 2025, Koios anticipates continued double-digit annual revenue expansion through its partnerships with GE Healthcare, Philips, Optum, and others, as additional reimbursement codes and global distribution drive adoption.

Our foundation is strong, and the next chapter is all about scale and scope expansion.

Forward-looking projections are not guaranteed.

Koios sits in the same category as recent billion-dollar imaging AI success stories. Companies like Viz.ai ($1.2B+), Aidoc ($1B+), and HeartFlow ($2.4B) have proven the appetite for clinically validated, diagnostic imaging platforms.

Forward-looking projections are not guaranteed.

Koios’ deep integrations with widely used machines from GE Healthcare and Philips — both active acquirers in medical AI — make it highly visible to strategic buyers.

As original equipment manufacturers (OEMs) and other global imaging leaders consolidate their AI ecosystems, Koios’ patented SmartUltrasound™ platform represents a turnkey acquisition with an existing global footprint and massive scale potential.

Koios has done what few early-stage AI companies achieve: FDA clearance, insurance coverage, global adoption, and revenue growth. The next phase is growth capital-fueled scaling, and it’s already well underway.

Koios is on a mission to make confident, accurate diagnosis the global standard of care. Our FDA-cleared SmartUltrasound™ is already trusted in more than 1,000 hospitals and clinics across 30+ countries, including leading institutions like Mount Sinai, Mayo Clinic, and Sloan, and partnered with industry giants GE Healthcare, Philips, and backed by Mitsui & Co.

Together, we can create a world where no cancer is missed, and every diagnosis is made with confidence.

Let’s make certainty the new standard of care. Invest in Koios today.